Plasma leptin levels and risk of incident cancer: Results from the dallas heart study

PLoS ONE

Volumn 11, Issue 9, 2016, Pages

  Gupta, Arjun ^a   Herman, Yehuda ^b   Ayers, Colby ^c   Beg, Muhammad S ^a   Lakoski, Susan G ^d   Abdullah, Shuaib M ^c   Johnson, David H ^a   Neeland, Ian J ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Department of Geology and Environmental Science   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEPTIN; TUMOR MARKER;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ETHNIC DIFFERENCE; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; POSTMENOPAUSE; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; SEX DIFFERENCE; SMOKING; WAIST CIRCUMFERENCE; WEIGHT HEIGHT RATIO; BLOOD; MIDDLE AGED; NEOPLASM; RISK FACTOR; TEXAS;

ADULT; BIOMARKERS, TUMOR; FEMALE; HUMANS; LEPTIN; MALE; MIDDLE AGED; NEOPLASMS; RISK FACTORS; TEXAS;

EID: 84992366120     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0162845     Document Type: Article

References (37)

1. Wannamethee SG, Tchernova J, Whincup P, Lowe GD, Kelly A, Rumley A, et al. Plasma leptin: Associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. Atherosclerosis. 2007; 191(2):418-26.
2. Garofalo C, Surmacz E. Leptin and cancer. Journal of cellular physiology. 2006; 207(1):12-22.
3. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: A systematic review and meta-Analysis of prospective observational studies. Lancet. 2008; 371 (9612):569-78. doi: 10.1016/S0140-6736(08)60269-X
4. Hsing AW, Chua S Jr., Gao YT, Gentzschein E, Chang L, Deng J, et al. Prostate cancer risk and serum levels of insulin and leptin: A population-based study. Journal of the National Cancer Institute. 2001; 93 (10):783-9.
5. Aleksandrova K, Boeing H, Jenab M, Bueno-de-Mesquita HB, Jansen E, van Duijnhoven FJ, et al. Leptin and soluble leptin receptor in risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition cohort. Cancer research. 2012; 72(20):5328-37. doi: 10.1158/0008-5472.CAN-12-0465
6. Baillargeon J, Platz EA, Rose DP, Pollock BH, Ankerst DP, Haffner S, et al. Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer epidemiology, biomarkers & prevention: A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006; 15(7):1331-5.
7. Chen CL, Yang WS, Yang HI, Chen CF, You SL, Wang LY, et al. Plasma adipokines and risk of hepatocellular carcinoma in chronic hepatitis B virus-infected carriers: A prospective study in taiwan. Cancer epidemiology, biomarkers & prevention: A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2014; 23(8):1659-71.
8. Harris HR, Tworoger SS, Hankinson SE, Rosner BA, Michels KB. Plasma leptin levels and risk of breast cancer in premenopausal women. Cancer prevention research. 2011; 4(9):1449-56. doi: 10. 1158/1940-6207.CAPR-11-0125
9. Ollberding NJ, Kim Y, Shvetsov YB, Wilkens LR, Franke AA, Cooney RV, et al. Prediagnostic leptin, adiponectin, C-reactive protein, and the risk of postmenopausal breast cancer. Cancer prevention research. 2013; 6(3):188-95. doi: 10.1158/1940-6207.CAPR-12-0374
10. Petridou E, Belechri M, Dessypris N, Koukoulomatis P, Diakomanolis E, Spanos E, et al. Leptin and body mass index in relation to endometrial cancer risk. Annals of nutrition & metabolism. 2002; 46(3-4):147-51.
11. Petridou E, Papadiamantis Y, Markopoulos C, Spanos E, Dessypris N, Trichopoulos D. Leptin and insulin growth factor I in relation to breast cancer (Greece). Cancer causes & control: CCC. 2000; 11 (5):383-8.
12. Wu MH, Chou YC, Chou WY, Hsu GC, Chu CH, Yu CP, et al. Circulating levels of leptin, adiposity and breast cancer risk. British journal of cancer. 2009; 100(4):578-82. doi: 10.1038/sj.bjc.6604913
13. Wu MM, Chen HC, Chen CL, You SL, Cheng WF, Chen CA, et al. A prospective study of gynecological cancer risk in relation to adiposity factors: cumulative incidence and association with plasma adipokine levels. PloS one. 2014; 9(8):e104630. doi: 10.1371/journal.pone.0104630
14. Yeung CY, Tso AW, Xu A, Wang Y, Woo YC, Lam TH, et al. Pro-inflammatory adipokines as predictors of incident cancers in a Chinese cohort of low obesity prevalence in Hong Kong. PloS one. 2013; 8(10): e78594. doi: 10.1371/journal.pone.0078594
15. Victor RG, Haley RW, Willett DL, Peshock RM, Vaeth PC, Leonard D, et al. The Dallas Heart Study: A population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. The American journal of cardiology. 2004; 93(12):1473-80.
16. Abdullah SM, Khera A, Leonard D, Das SR, Canham RM, Kamath SA, et al. Sex differences in the association between leptin and CRP: results from the Dallas Heart Study. Atherosclerosis. 2007; 195 (2):404-10.
17. Chandra A, Neeland IJ, Berry JD, Ayers CR, Rohatgi A, Das SR, et al. The relationship of body mass and fat distribution with incident hypertension: observations from the Dallas Heart Study. Journal of the American College of Cardiology. 2014; 64(10):997-1002. doi: 10.1016/j.jacc.2014.05.057
18. Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. Jama. 2012; 308(11):1150-9.
19. Beg MS, Saleem S, Turer A, Ayers C, de Lemos JA, Khera A, et al. A Prospective Analysis of Plasma Adiponectin and Risk of Incident Cancer: The Dallas Heart Study. Journal of the National Comprehensive Cancer Network: JNCCN. 2015; 13(7):873-8.
20. National Cancer Institute. [Accessed November 15 OaCRJ, 2012. http://www.cancer.gov/aboutcancer/causes-prevention/risk/obesity/obesity-fact-sheet
21. Aparicio T, Kotelevets L, Tsocas A, Laigneau JP, Sobhani I, Chastre E, et al. Leptin stimulates the proliferation of human colon cancer cells in vitro but does not promote the growth of colon cancer xenografts in nude mice or intestinal tumorigenesis in Apc(Min/+) mice. Gut. 2005; 54(8):1136-45.
22. Li H, Stampfer MJ, Mucci L, Rifai N, Qiu W, Kurth T, et al. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clinical chemistry. 2010; 56 (1):34-43. doi: 10.1373/clinchem.2009.133272
23. Stattin P, Kaaks R, Johansson R, Gislefoss R, Soderberg S, Alfthan H, et al. Plasma leptin is not associated with prostate cancer risk. Cancer epidemiology, biomarkers & prevention: A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2003; 12(5):474-5.
24. Lai GY, Giovannucci EL, Pollak MN, Peskoe SB, Stampfer MJ, Willett WC, et al. Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study. Cancer causes & control: CCC. 2014; 25(5):625-32.
25. Gong TT, Wu QJ, Wang YL, Ma XX. Circulating adiponectin, leptin and adiponectin-leptin ratio and endometrial cancer risk: Evidence from a meta-Analysis of epidemiologic studies. International journal of cancer. 2015; 137(8):1967-78. doi: 10.1002/ijc.29561
26. Niu J, Jiang L, Guo W, Shao L, Liu Y, Wang L. The Association between Leptin Level and Breast Cancer: A Meta-Analysis. PloS one. 2013; 8(6):e67349. doi: 10.1371/journal.pone.0067349
27. Wulaningsih W, Holmberg L, Ng T, Rohrmann S, Van Hemelrijck M. Serum leptin, C-reactive protein, and cancer mortality in the NHANES III. Cancer medicine. 2016; 5(1):120-8. doi: 10.1002/cam4.570
28. Joshi RK, Lee SA. Obesity related adipokines and colorectal cancer: A review and meta-Analysis. Asian Pacific journal of cancer prevention: APJCP. 2014; 15(1):397-405.
29. Song CH, Liao J, Deng ZH, Zhang JY, Xue H, Li YM, et al. Is leptin a predictive factor in patients with lung cancer? Clinical biochemistry. 2014; 47(3):230-2. doi: 10.1016/j.clinbiochem.2013.12.003
30. Kerem M, Ferahkose Z, Yilmaz UT, Pasaoglu H, Ofluoglu E, Bedirli A, et al. Adipokines and ghrelin in gastric cancer cachexia. World journal of gastroenterology. 2008; 14(23):3633-41.
31. Engineer DR, Garcia JM. Leptin in anorexia and cachexia syndrome. International journal of peptides. 2012; 2012:287457. doi: 10.1155/2012/287457
32. Bologna M, Patrizia S, Vicentini C, Angelucci A. Aging Influences the Value of Serum Leptin as Prostate Cancer Risk Factor. Oncology & Hematology Review. 2013; 9(1):10-5.
33. Frederich R, Hu S, Raymond N, Pomeroy C. Leptin in anorexia nervosa and bulimia nervosa: importance of assay technique and method of interpretation. The Journal of laboratory and clinical medicine. 2002; 139(2):72-9.
34. Song M, Zhang X, Wu K, Ogino S, Fuchs CS, Giovannucci EL, et al. Plasma adiponectin and soluble leptin receptor and risk of colorectal cancer: A prospective study. Cancer prevention research. 2013; 6 (9):875-85. doi: 10.1158/1940-6207.CAPR-13-0169
35. Liu P, Shi H, Liu R, Yang Y, Yang Y, Huang C, et al. Lack of association between LEPR Q223R polymorphisms and cancer susceptibility: evidence from a meta-Analysis. Journal of BUON: official journal of the Balkan Union of Oncology. 2014; 19(3):855-62.
36. Unsal M, Kara N, Karakus N, Tural S, Elbistan M. Effects of leptin and leptin receptor gene polymorphisms on lung cancer. Tumour biology: The journal of the International Society for Oncodevelopmental Biology and Medicine. 2014; 35(10):10231-6.
37. Snoussi K, Strosberg AD, Bouaouina N, Ben Ahmed S, Helal AN, Chouchane L. Leptin and leptin receptor polymorphisms are associated with increased risk and poor prognosis of breast carcinoma. BMC cancer. 2006; 6:38.